AUS
NZ
UK
CA
USA
IND
Highlights
- R327 demonstrates strong antibacterial effect in preclinical tests
- Nebulised delivery offers real-world hospital advantage
- Research expands synthetic anti-infective pipeline
Recce Pharmaceuticals (ASX:RCE) has delivered compelling preclinical results for its inhaled anti-infective candidate, RECCE® 327 (R327), demonstrating significant antibacterial activity against multidrug-resistant pneumonia. Conducted in collaboration with the Murdoch Children’s Research Institute (MCRI), the study focused on hospital- and ventilator-acquired pneumonia (HAP/VAP), with findings showcasing the unique advantages of nebulised R327 in targeted lung delivery.
The study highlighted R327's strong effect against Acinetobacter baumannii, a challenging superbug known for causing severe infections in hospital environments. The research builds on prior studies, illustrating the compound’s broad-spectrum synthetic anti-infective capability and supporting ongoing expansions in both clinical and preclinical programs throughout recent years, including Phase 3 trials in wound infections and ongoing dosing studies for diabetic foot infections.
Strong Antibacterial Performance in Preclinical Tests
The preclinical evaluation compared intranasal and nebulised R327 against placebo, saline, and conventional last-resort antibiotics. R327 demonstrated significant reductions in bacterial lung load shortly after administration, showing a level of infection control consistent with strong localised therapeutic effects. Notably, the nebulised format allows R327 to be delivered directly into the lungs via nebulisers or ventilators, a method that many standard antibiotics cannot match due to solubility challenges.
Beyond bacterial reduction, preliminary results showed positive effects on inflammatory markers, indicating R327's potential role in mitigating lung inflammation during severe infections. The therapy was well tolerated in all tested delivery methods, supporting its adaptability for hospital use.
Real-World Advantages in Severe Lung Infections
The inhaled delivery method of R327 represents a practical advantage in acute care settings. Hospitals can leverage this delivery in intensive care units and emergency departments to administer rapid, localised treatment for patients with drug-resistant lung infections. This flexibility enhances treatment efficiency and opens new avenues for addressing challenging respiratory infections where conventional antibiotics may fail.
R327’s activity against multidrug-resistant A. baumannii contributes to a growing body of evidence supporting its relevance in the global fight against antibiotic-resistant pathogens. With drug-resistant infections recognized as a critical health challenge worldwide, therapies such as R327 are increasingly vital in hospital settings.
Expanding Synthetic Anti-Infective Research
Recce and MCRI established the Anti-Infective Research (AIR) Unit to investigate R327 across various infection models, including respiratory, sepsis, and wound infections. These studies inform formulation optimisation, dosing strategies, and regulatory preparations for both inhaled and topical applications. R327 is complemented by Recce’s broader pipeline, which includes oral anti-infective R435 and antiviral R529.
The company’s innovative approach to synthetic anti-infectives aligns with trends in the ASX stock market and demonstrates potential for integration within broader pharmaceutical and healthcare developments tracked by ASX100 and ASX300 companies. Investors and analysts following healthcare technology can monitor how Recce’s advances in drug-resistant therapies may influence the sector, including potential links to wider ASX dividend stocks and ASX mining stocks portfolios focusing on innovation and sustainable solutions.
R327’s preclinical success reinforces Recce’s commitment to developing versatile synthetic anti-infectives capable of addressing multidrug-resistant pathogens. As the research progresses, inhaled R327 may offer a new standard in treating complex respiratory infections, while broader pipeline developments continue to explore innovative solutions in oral and antiviral therapies.
